Q1 due 4 May; trends continue to look positive... .
Redeye sees a Q1 report that did not meet our high expectations.
Q1e: We expect SEK 35.5m revenue and 11.4m EBIT '23e-'25e sales reduced by 3-7% on lowered FX and cu...
Redeye provides a research update following the Q2 report published by Newbury yesterday.
Sales down 35% y-o-y in Q1 EBIT likely negative as a result Both business areas affected Worrying t...
No new orders in Q1, one new order in Q2 Quarterly goodwill amortisation to double: SEK 6m to SEK 12...
Wyld, har efter lansering av dess satellit-IoT-nätverkstjänst erhållit en kraftigt växande orderbok.
Redeye updated our Biovica outlook after securing access to growth capital and initiating the US and...
Redeye updates its estimates following the ground-breaking news of the establishment of a Joint Vent...
Redeye leaves an initial comment following the Q2 report published by Newbury this morning.
(Rättelsen är ett förtydligande om att det handlar om åtta europeiska länder, ej kliniker) Rapportko...
Rapportkommentar Diamyds Q2-rapport för det brutna räkenskapsåret 22/23 var i linje med våra förvänt...
In line with its ambitious growth plan, Agtira is now expanding its engagement with grocery producer...
Lipigon avancerar vidare med god säkerhetsprofil i fas I-studien med Lipisense som nu närmar sig sit...
Redeye comments on ISAB’s rights issue announcement of approximately SEK17.
No indication of consumer rebound yet '23e EBIT down 5%, '24e-'25e unchanged 8.
Ett område som står inför en accelererande tillväxt Vi har tittat närmare på Mentice exponering mot ...
Fortsätter växa kraftigt… LEVELs tillgängliga marknad växer med ca 8% per år och LEVEL fortsätter at...
Endomines reported strong production figures for Pampalo as the production increased 215% y/y during...
Redeye comments on Sivers' announced financing solution consisting of a SEK150m directed share issue...
